The DOI matches its Crossref record.
Oligomers on the Brain: the Emerging Role of Soluble Protein Aggregates in Neurodegeneration.
Abstract
Extracellular fibrous amyloid deposits or intracellular inclusion bodies containing abnormal protein fibrils characterize many different neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), dementia with Lewy bodies, multiple system atrophy, Huntington's disease, and the transmissible 'prion' dementias. There is strong evidence from genetic, transgenic mouse and biochemical studies to support the idea that the accumulation of protein aggregates in the brain plays a seminal role in the pathogenesis of these diseases. How monomeric proteins ultimately convert to highly polymeric deposits is unknown. However, studies employing, synthetic, cell-derived and purified recombinant proteins suggest that amyloid proteins first come together to form soluble low n-oligomers. Further association of these oligomers results in higher molecular weight assemblies including so-called 'protofibrils' and 'ADDLs' and these eventually exceed solubility limits until, finally, they are deposited as amyloid fibrils. With particular reference to AD and PD, we review recent evidence that soluble oligomers are the principal pathogenic species that drive neuronal dysfunction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Neuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Involvement of oxidative stress in Alzheimer disease
Nunomura, A., Castellani, R. J., Zhu, X., Moreira, P. I., Perry, G., & Smith, M. A. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000228136.58062.bf · Cited by 611
Folding versus aggregation: Polypeptide conformations on competing pathways
Jahn, T. R., & Radford, S. E. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.05.015 · Cited by 428
Molecular Mechanisms of Amyloid Oligomers Toxicity
Kayed, R., & Lasagna-Reeves, C. A. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129001 · Cited by 415
Wu, Y., Wu, Z., Butko, P., Christen, Y., Lambert, M. P., Klein, W. L., Link, C. D., & Luo, Y. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3448-06.2006 · Cited by 406
Aβ inhibits the proteasome and enhances amyloid and tau accumulation
Tseng, B. P., Green, K. N., Chan, J. L., Blurton-Jones, M., & LaFerla, F. M. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.014 · Cited by 384
Heat Shock Proteins 70 and 90 Inhibit Early Stages of Amyloid β-(1–42) Aggregation in Vitro
Evans, C. G., Wisén, S., & Gestwicki, J. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m606192200 · Cited by 382
Crews, L., Spencer, B., Desplats, P., Patrick, C., Paulino, A., Rockenstein, E., Hansen, L., Adame, A., Galasko, D., & Masliah, E. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009313 · Cited by 367
RetractedYang, T., Li, S., Xu, H., Walsh, D. M., & Selkoe, D. J. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1698-16.2016 · Cited by 347
Self-citationA common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers
Thibaudeau, T. A., Anderson, R. T., & Smith, D. M. (2018) · Nature Communications · doi:10.1038/s41467-018-03509-0 · Cited by 360
Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Uversky, V., & Eliezer, D. (2009) · Current Protein & Peptide Science · doi:10.2174/138920309789351921 · Cited by 322
Paleček, E., Tkáč, J., Bartošík, M., Bertók, T., Ostatná, V., & Paleček, J. (2015) · Chemical Reviews · doi:10.1021/cr500279h · Cited by 319
Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
Lombardo, S., & Maskos, U. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.11.018 · Cited by 299
A critical appraisal of the pathogenic protein spread hypothesis of neurodegeneration
Walsh, D. M., & Selkoe, D. J. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.13 · Cited by 294
Self-citationAtamna, H., & Boyle, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600134103 · Cited by 290
Miller, Y., Ma, B., & Nussinov, R. (2010) · Chemical Reviews · doi:10.1021/cr900377t · Cited by 286
Tsigelny, I. F., Crews, L., Desplats, P., Shaked, G. M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003135 · Cited by 281
RetractedMultiple Assembly Pathways Underlie Amyloid-β Fibril Polymorphisms
Goldsbury, C., Frey, P., Olivieri, V., Aebi, U., & Müller, S. A. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.07.029 · Cited by 273
Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease
Overk, C. R., & Masliah, E. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.015 · Cited by 242
Ricobaraza, A., Cuadrado‐Tejedor, M., Marco, S., Pérez‐Otaño, I., & García‐Osta, A. (2012) · Hippocampus · doi:10.1002/hipo.20883 · Cited by 239
Are tau aggregates toxic or protective in tauopathies?
Cowan, C. M., & Mudher, A. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00114 · Cited by 215
Hung, L. W., Ciccotosto, G. D., Giannakis, E., Tew, D. J., Perez, K., Masters, C. L., Cappai, R., Wade, J. D., & Barnham, K. J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3916-08.2008 · Cited by 210
Kirouac, L., Rajic, A. J., Cribbs, D. H., & Padmanabhan, J. (2017) · eneuro · doi:10.1523/eneuro.0149-16.2017 · Cited by 207
“Soluble, small A oligomers are toxic to neurons (Klein et al. 2001; Walsh and Selkoe, 2004); however, the mechanisms by which oligomeric A leads to synaptic dysfunction and neurodegeneration are not fully understood.”
BackgroundPham, E., Crews, L., Ubhi, K., Hansen, L., Adame, A., Cartier, A., Salmon, D., Galasko, D., Michael, S., Savas, J. N., et al. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07719.x · Cited by 206
Broersen, K., Rousseau, F., & Schymkowitz, J. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt36 · Cited by 168
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model
Garcia-Alloza, M., Dodwell, S. A., Meyer-Luehmann, M., Hyman, B. T., & Bacskai, B. J. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/01.jnen.0000240468.12543.af · Cited by 99
Golde, T. E., & Miller, V. M. (2009) · Alzheimer's Research & Therapy · doi:10.1186/alzrt5 · Cited by 98
Targeting Aβ and tau in Alzheimer's disease, an early interim report
Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89
“Indeed, the relationship of oligomeric assemblies 254 T.E.G olde et al./ Experim ental N eurology 223 (2010) 252 –266 to cognitive deficits in humans remains to be established (Walsh and Selkoe, 2004b; Glabe, 2006).”
Inhibition of APP Trafficking by Tau Protein Does Not Increase the Generation of Amyloid‐β Peptides
Goldsbury, C., Mocanu, M., Thies, E., Kaether, C., Haass, C., Keller, P., Biernat, J., Mandelkow, E., & Mandelkow, E. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00434.x · Cited by 82
Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex
Sepulcre, J., Grothe, M. J., Sabuncu, M., Chhatwal, J., Schultz, A. P., Hanseeuw, B., El Fakhri, G., Sperling, R., & Johnson, K. A. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0263 · Cited by 73
Garcia, P., Jürgens‐Wemheuer, W., Uriarte Huarte, O., Michelucci, A., Masuch, A., Brioschi, S., Weihofen, A., Koncina, E., Coowar, D., Heurtaux, T., et al. (2022) · Glia · doi:10.1002/glia.24149 · Cited by 65
Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Campos-Peña, V., Toral-Rios, D., Becerril-Pérez, F., Sánchez-Torres, C., Delgado-Namorado, Y., Torres-Ossorio, E., Franco-Bocanegra, D., & Carvajal, K. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6768 · Cited by 58
Heiner, F., Feistel, B., & Wink, M. (2018) · PeerJ · doi:10.7717/peerj.4683 · Cited by 40
Abd El-Aziz, N. M. A., Shehata, M. G., Alsulami, T., Badr, A. N., Elbakatoshy, M. R., Ali, H. S., & El-Sohaimy, S. A. (2022) · Pharmaceuticals · doi:10.3390/ph16010012 · Cited by 31
Liu, H.-P., Lin, W.-Y., Liu, S.-H., Wang, W.-F., Tsai, C.-H., Wu, B.-T., Wang, C.-K., & Tsai, F.-J. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000254757 · Cited by 29
Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29
Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses
Kadamangudi, S., Marcatti, M., Zhang, W.-R., Fracassi, A., Kayed, R., Limon, A., & Taglialatela, G. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02839-2 · Cited by 25
Metadata
- Authors
- Walsh, D., & Selkoe, D.
- Venue
- Protein & Peptide Letters
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-06-01
- Volume
- 11
- Issue
- 3
- Pages
- 213-228
- ISSN
- 0929-8665 (ISSN-L)
- OpenAlex
- W2071982060
- Cited by
- 428
- References
- 0
- FWCI
- 16.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.